%0 Journal Article
%A Sapena, Victor
%A Enea, Marco
%A Torres, Ferran
%A Celsa, Ciro
%A Rios, Jose
%A Rizzo, Giacomo Emanuele Maria
%A Nahon, Pierre
%A Mariño, Zoe
%A Tateishi, Ryosuke
%A Minami, Tatsuya
%A Sangiovanni, Angelo
%A Forns, Xavier
%A Toyoda, Hidenori
%A Brillanti, Stefano
%A Conti, Fabio
%A Degasperi, Elisabetta
%A Yu, Ming-Lung
%A Tsai, Pei-Chien
%A Jean, Kevin
%A El Kassas, Mohamed
%A Shousha, Hend Ibrahim
%A Omar, Ashraf
%A Zavaglia, Claudio
%A Nagata, Hiroko
%A Nakagawa, Mina
%A Asahina, Yasuhiro
%A Singal, Amit G
%A Murphy, Caitlin
%A Kohla, Mohamed
%A Masetti, Chiara
%A Dufour, Jean-François
%A Merchante, Nicolas
%A Cavalletto, Luisa
%A Chemello, Liliana Lc
%A Pol, Stanislas
%A Crespo, Javier
%A Calleja, Jose Luis
%A Villani, Rosanna
%A Serviddio, Gaetano
%A Zanetto, Alberto
%A Shalaby, Sarah
%A Russo, Francesco Paolo
%A Bielen, Rob
%A Trevisani, Franco
%A Cammà, Calogero
%A Bruix, Jordi
%A Cabibbo, Giuseppe
%A Reig, Maria
%T Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
%D 2021
%U http://hdl.handle.net/10668/20154
%X The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I2=74.6%) and 5.7 (2.5 to 15.3, I2=54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.
%K antiviral therapy
%K hepatocellular carcinoma
%K meta-analysis
%~